News | February 26, 2013

Sniffing Out the Side Effects of Radiotherapy May Soon Be Possible

February 26, 2013 — Researchers at the University of Warwick and The Royal Marsden NHS Foundation Trust have completed a clinical study that may lead to clinicians being able to more accurately predict which patients will suffer from the side effects of radiotherapy.

Gastrointestinal side effects are commonplace in radiotherapy patients and occasionally severe, yet there is no existing means of predicting which patients will suffer from them. The results of the pilot study, published in the journal Sensors, outline how the use of an electronic nose and a newer technology, FAIMS (field asymmetric ion mobility spectrometry) might help identify those at higher risk.

Warwick Medical School, working in collaboration with the School of Engineering and The Royal Marsden NHS Foundation Trust (led by Dr. J Andreyev), carried out a pilot study to look into the relationship between levels of toxicity in the gut and the likelihood of experiencing side effects.

Dr. Ramesh Arasaradnam, of Warwick Medical School and Gastroenterologist at University Hospitals Coventry and Warwickshire, outlines the results of the study. "In the simplest terms, we believe that patterns in toxicity levels arise from differences in a patient's gut microflora. By using this technology we can analyze stool samples and sniff out the chemicals that are produced by these microflora to better predict the risk of side effects."

The success of the pilot study will lead to a broader investigation into the possible uses of these technologies and could be truly significant in helping clinicians inform patients receiving pelvic radiotherapy, before treatment is started.

Arasaradnam explains what this could mean for radiotherapy patients, "In essence, we will be able to predict those who are likely to develop severe gut related side effects by the pattern of gut fermentation that are altered as a result of radiotherapy. This will enable future directed therapy in these high risk groups."

Dr. James Covington, from the Warwick School of Engineering adds, "This technology offers considerable opportunities for the future. This shows just one application of being able to inform treatment by 'sniffing' patients. We foresee a time when such technology will become as routine a diagnostic test as checking blood pressure is today."

It is further evidence of the ongoing collaboration between Warwick Medical School and School of Engineering. This technology, first developed at Warwick in the early 1990s has been in continuous development ever since, producing some of the most sophisticated chemical sensors and sensor systems available today.

In 2009, the same high tech gas sensor was taken from the automotive world and used to research into quicker diagnosis for some gastrointestinal illnesses and metabolic diseases.

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...